Allogene Therapeutics, Inc. (ALLO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.97-0.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ALLO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 474.5% |
| Our one-year growth estimate | diamond | 64.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 410.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ALLO — CFO transition
Dated 2026-09-02
CFO — Geoffrey Parker: The CFO is retiring with advance notice, which constitutes an orderly succession rather than a sudden loss of a senior executive.
Why it matters: More active sites can help enroll more patients in the ALPHA3 trial. This is key for meeting timelines and showing demand.
Supportive ifAbout 100 sites are active and enrolling patients in the ALPHA3 trial.
Worry ifSite activation stalls or fails to reach the target of 100 active sites by year-end 2026.
Why it matters: Positive results could support cema-cel's potential as a new treatment for LBCL.
Supportive ifThe interim analysis shows MRD clearance over 25%. This is compared to the observation group.
Worry ifMRD clearance is below 25%, suggesting cema-cel may not be effective.
Why it matters: Changes in leadership may change company priorities. This can affect investor trust.
Watch forThe new CEO shares a clear plan that matches investor interests.
Also watch forThe new CEO does not share a clear strategy, causing uncertainty.
Why it matters: A strong cash position is vital for funding ongoing trials and operations. This update will signal financial stability.
Supportive ifManagement says they have enough cash to operate until 2029.
Worry ifCash runway estimates are lower. This suggests there may be funding issues.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$242 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $688 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,575 loss on $10,000 · 45.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Managing expenses is crucial for financial health. Staying within this range shows effective cost control.
Supportive ifOperating expenses reported within $210M-$225M range for the year.
Worry ifOperating expenses are over $225M. This shows poor cost management.
Why it matters: This update will show how well ALLO-329 works for autoimmune diseases. Good data could help investors.
Supportive ifClinical data shows that ALLO-329 works well and is tolerated by patients.
Worry ifData shows no signs of problems with ALLO-329 in patients.
Why it matters: This could impact product strategy and partnerships. Clarity on next steps is crucial.
Watch forA new partnership or strategy will be announced after the deal ends.
Also watch forFurther delays or lack of clarity on future product plans.